Laboratory of Neuropsychopharmacology Homepage
Recent Publications
2004
Arborelius L, Hawks BW, Owens MJ, Plotsky PM, Nemeroff CB. Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation.Psychopharmacology (Berl). 2004 Nov;176(3-4):248-55. Epub 2004 Nov.
Binder EB, Kinkead B, Owens MJ, Nemeroff CB. Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs.Neuropsychopharmacology. 2004 Dec;29(12):2200-7.
Carpenter LL, Tyrka AR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology. 2004 Apr;29(4):777-84.
Douglas Bremner J, Mletzko T, Welter S, Siddiq S, Reed L, Williams C, Heim CM, Nemeroff CB. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study.J Clin Psychiatry. 2004 Nov;65(11):1559-64.
Kinkead B, Nemeroff CB. Neurotensin, schizophrenia, and antipsychotic drug action. Int Rev Neurobiol. 2004;59:327-49. Review.
McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Camp VM, Votaw JR, Nemeroff CB, Goodman MM. Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nucl Med Biol. 2004 Aug;31(6):705-18.
Nemeroff CB. 2004. Neurobiological consequences of childhood trauma. Neurobiological consequences of childhood trauma. J Clin Psychiatry. 2004;65 Suppl 1:18-28. Review.
Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 2004 Jun;9(6 Suppl 4):23-31. Review.
Newport DJ, Owens MJ, Knight DL, Ragan K, Morgan N, Nemeroff CB, Stowe ZN. Alterations in platelet serotonin transporter binding in women with postpartum onset major depression.J Psychiatr Res. 2004 Sep-Oct;38(5):467-73.
Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65 Suppl 4:5-10. Review.
Rush AJ, Trivedi MH, Carmody TJ, Ibrahim HM, Markowitz JC, Keitner GI, Kornstein SG, Arnow B, Klein DN, Manber R, Dunner DL, Gelenberg AJ, Kocsis JH, Nemeroff CB, Fawcett J, Thase ME, Russell JM, Jody DN, Borian FE, Keller MB. Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients Neuropsychopharmacology. 2004 Dec 01.
Selz KA, Mandell AJ, Shlesinger MF, Arcuragi V, Owens MJ. Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators. Biophys J. 2004 Mar;86(3):1308-31.
Skelton KH, Nemeroff CB, Owens MJ. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression.J Neurosci. 2004 Oct 20;24(42):9303-12.
Tyrka AR, Carpenter LL, McDougle CJ, Kirwin PD, Owens MJ, Nemeroff CB, Strong DR, Price LH. Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biol Psychiatry. 2004 Oct 1;56(7):531-4.
Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2.
2003
Berns GS and Nemeroff CB. 2003. The neurobiology of bipolar disorder. Amer J Medical Genetics 123C:76-84.
Caceda R. Kinkead B. Nemeroff CB. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? Seminars in Clinical Neuropsychiatry. 8(2):94-108, 2003.
Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D and Miller AH. 2003. Interferon-alpha-induces changes in tryptohan metabolism: relationship to depression and paroxetine treatment. Biol Psychiat 54:906-914.
Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB and Miller AH. 2003. An exaggerated HPA axis response to the initial injection of interferon-alpha is associated with the development of depression during interferon-alpha therapy. Am J Psychiat 160:1342-1345.
Garlow SJ and Nemeroff CB. 2003. Neurobiology of depressive disorders. In: Handbook of Affective Sciences, RJ Davidson KR Scherer and HH Goldsmith, Eds, Oxford University Press, 1021-1043.
Gilmor ML, Skelton KH, Nemeroff CB and Owens MJ. 2003. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J. Pharmacology & Experimental Therapeutics 305:434-439.
Goldberg S, Levitan RD, Leung E, Masellis M, Basile VS, Nemeroff CB and Atkinson L. 2003. Short term stability of cortisol stress responses in 12-18-month-old infants. Biol Psychiat 54:719-726.
Goodman MM, Chen P, Plisson C, Martarello L, Galt J, Votaw JR, Kilts CD, Malveux G, Camp VM, Shi B, Ely TD, Howell H, McConathy J and Nemeroff CB. 2003. Synthesis and characterization of iodine-123 labeled 2ß-carbomethoxy-3ß-(4-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography. J Med Chem 46:925-935.
Gutman DA, Musselman DL and Nemeroff CB. 2003. Neuropeptide alterations in depression and anxiety disorders. In: Handbook of Depression and Anxiety, 2 nd edition, ( S Kasper , JA denBoer, and JM AdSitsen, eds), Marcel Dekker, Inc. 229-265.
Gutman DA and Nemeroff CB. 2003. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. Physiol Behav 79:471-478.
Gutman DA, Owens MJ and Nemeroff CB. 2003. Corticotropin-releasing factor receptor and glucocorticoid receptor antagonists: new approaches to antidepressant treatment. In: Current and Future Developments in Psychopharmacology (JA denBoer, ed), (in press).
Gutman DA, Owens MJ, Skelton KH, Thrivikraman KV and Nemeroff CB. 2003. The CRF 1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Therapeut 304:874-880.
Heim C, Meinlschmidt G and Nemeroff CB. 2003. The neurobiology of early-life stress and its relationship to PTSD. Psychiatric Annals 33:18-26
Kinkead B and Nemeroff CB. 2003. Neurotensin. In: Encyclopedia of Neuroscience, 3rd Edition (G Adelman and BH Smith, Eds), Elsevier Press (in press).
Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW and Nemeroff CB. 2003. Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. Neuropsychopharmacol 28:1186-1197.
Kinkead B and Nemeroff CB. 2003. Neurotensin. In: Encyclopedia of Neuroscience, 3 rd Edition (G Adelman and BH Smith, Eds), Elsevier Press (in press).
Kinkead B and Nemeroff CB. 2003. Neurotensin, schizophrenia and antipsychotic drug actions. In: Disorders of Synaptic Plasticity (J Smythies, ed), International Review of Neurobiology (in press).
Mandell AJ, Selz KA, Owens MJ and Shlesinger MF. 2003. Broomhead-King hydrophobic modes in receptor-targeted peptide design: how to find modes in a short data sequence. In: Unsolved Problems of Noise (L Kish and S Bezrukov, eds), Am. Inst. Physics Press, College Park MD, (in press).
Mandell AJ, Selz KA, Owens MJ, Kinkead B, Shlesinger MF, Gutman DA and Arcuragi V. 2003. Cellular and behavioral effects of the D2 dopamine receptor hydrophobic eigenmode-targeted peptide ligands. Neuropsychopharmacology 2003 Jul;28 Suppl 1:S98-107.
Marcin MS and Nemeroff CB. 2003. The neurobiology of social anxiety: the relevance of fear and anxiety. Acta Psychiat Scand 108:51-64.
McConathy J, Owens MJ, Kilts CV, Malveaux EJ, Camp VM, Votaw JR, Nemeroff CB and Goodman MM. 2003. Synthesis and biological evaluations of [ 11C]talopram and [ 11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nuclear Medicine and Biology (in press).
McConathy J and Owens MJ. 2003. Stereochemistry and drug action. J. Clinical Psychiatry – Primary Care Companion (in press).
Musselman DL and Nemeroff CB. 2003. Neuropeptides and hypothalamic releasing factors in psychiatric illness. In: Psychoneuroendocrinology: The Scientific Basis of Clinical Practice (OM Wolkowitz and AJ Rothschild, eds), American Psychiatric Press, 29-82.
Nemeroff CB. 2003. Anxiolytics: past, present, and future agents. J Clin Psychiat 64:3-6.
Nemeroff CB. 2003. Improving antidepressant adherence. J Clin Psychiat (in press).
Nemeroff CB. 2003. Overview of the safety of citalopram. Psychopharmacol Bull 37:96-121.
Nemeroff CB. 2003. Advancing the treatment of mood and anxiety disorders: the first 10 years'
experience with paroxetine.
Psychopharmacol Bull. 2003 Spring;37 Suppl 1:6-7.
Nemeroff CB. 2003. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharm Bull (in press).
Nemeroff CB. 2003. Unmet needs and the neurobiology of depression. Mental Fitness 2:26-32.
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss P, Dunner DL, Rothbaum BO, Kornstein S, Keitner G and Keller MB. 2003. Differential responses to psychotherapy versus pharmacotherapy in the treatment of patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci 100:14293-14296.
Nemeroff CB and Putnam JS. 2003. " 2 -Adrenergic receptor agonists: clonidine and guanfacine. In: Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Eighth Edition (B Sadock and V Sadock, Eds), Lippincott Williams & Wilkins (in press).
Nemeroff CB and Putnam JS. 2003. Antihistamines. In: Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Eighth Edition (B Sadock and V Sadock, Eds), Lippincott Williams & Wilkins (in press).
Nemeroff CB and Putnam JS. 2003. Barbiturates and similarly acting substances. In: Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Eighth Edition (B Sadock and V Sadock, Eds), Lippincott Williams & Wilkins (in press).
Newport DJ, Heim C, Owens MJ, Ritchie JC, Ramsey C, Bonsall R, Miller AH and Nemeroff CB. 2003. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Neuropsychopharmacol 28:569-576.
Newport DJ, Heim C, Bonsall R, Miller AH and Nemeroff CB. 2003. Pituitary-adrenal responses to standard and low dose dexamethasone suppression tests in adult survivors of child abuse. Biol Psychiat (in press).
Newport DJ, Heim C, Owens MJ, Ritchie JC, Ramsey CH, Bonsall R, Miller AH and Nemeroff CB. 2003. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Neuropsychopharmacology 28:569-576.
Owens MJ and Ritchie JC. 2003. Clinical neurochemistry. In: Neurobiology of Mental Illness, 2nd edition (DS Charney, EJ Nestler and BS Bunney, Eds.), Oxford University Press, New York, (in press).
Owens MJ and Nemeroff CB. 2003. Neuropharmacology of paroxetine. Psychopharmacology Bulletin 37(S1):8-18.
Owens MJ and Nemeroff CB. 2003. Pharmacology of valproate. Psychopharmacol Bull. 2003;37 Suppl 2:17-24. Review
Penza KM, Heim C and Nemeroff CB. 2003. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Women’s Ment Health 6:15-22.
Purselle DC and Nemeroff CB. 2003. The serotonin transporter: a potential substrate in the biology of suicide. Neuropsychopharmacol 28:613-619.
Ressler KJ and Nemeroff CB. 2003. Depression. In: The Molecular and Genetic Basis of Neurologic and Psychiatric Disease, 3 rd edition. (RN Rosenberg, SB Prusiner, S DiMauro , RL Barchi and EJ Nestler, Eds), Butterworth-Heinemann, Philadelphia , 725-740.
Ritchie JC, Davis TP and Nemeroff CB. 2003. Action of three ectopeptidases on corticotropin-releasing factor: metabolism and functional aspects. Neuropsychopharmacol 28:22-33.
Rudisch B and Nemeroff CB. 2003. The epidemiology of comorbid coronary artery disease and depression. Biol Psychiat 54:227-240.
Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, vanZyl, LT, Finkel MS, Krishnan KRR, Gaffney M, Harrison W, Califf RM and O’Connor CM. 2003. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circulation 108:939-944.
Schlaepfer TE, Kosel M and Nemeroff CB. 2003. Efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of affective disorders. Neuropsychopharmacol 28:201-205.
Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS and Nemeroff CB. 2003. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiat 64:73-80.
Wang X and Nemeroff CB. 2003. Biological distinction between unipolar and bipolar disorder. In: Handbook of Medical Psychiatry, ( JC Soares and S Gershon, eds), Marcel Dekker, Inc, New York , 407-422.
Young LJ, Owens MJ and Nemeroff CB. 2003. Neuropeptides: biology, regulation and role in neuropsychiatric disorders. In: Comprehensive Textbook of Psychiatry, Eighth Edition (B Kaplan and V Sadock, Eds), Lippincott, Williams and Wilkins (in press).
2002
Arborelius L and Nemeroff CB. 2002. Preclinical models of anxiety. In: Textbook of Anxiety, D Stein and E Hollander, Eds, American Psychiatric Publishing, 29-42.
Binder EB, Gross RE, Nemeroff CB and Kilts CD. 2002. Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacol 161:288-295.
Boswell EB, Anfinson TJ and Nemeroff CB. 2002. Neuropsychiatric aspects of endocrine disorders. In: Textbook of Neuropsychiatry, 4th Edition (S. Yudofsky and R Hales, Eds.), American Psychiatric Association Press, Inc. Washington, DC, 851-875.
Capuron L, Gumnick JF, Musselman DL, Lawson D, Reemsynder A, Nemeroff CB and Miller AH. 2002. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol 26:643-652.
Charney DS, Nemeroff CB and the NDMDA Consensus Development Panel. 2002. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiat 59:262-270.
Cummins TK, Anand KJS and Nemeroff CB. 2002. Developmental psychoneuroendocrinology. In: Child and Adolescent Psychiatry: A Comprehensive Textbook, 3rd Edition, (M Lewis, Ed), Lippincott Williams & Wilkins, Baltimore, 93-119.
Davidson JT, Nemeroff CB and the Hypericum Depression Trial Study Group. 2002. Effect of hypericum perforatum ( St. John’s Wort) in major depressive disorder: a randomized controlled trial. JAMA 287:1807-1814.
Gilmor M, Owens MJ and Nemeroff CB. 2002. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiat 159:1702-1710.
Gutman DA and Nemeroff CB. 2002. Neurobiology of early life stress: rodent studies. Seminars in Clinical Neuropsychiatry 7:89-95.
Gutman DA and Nemeroff CB. 2002. Neuroendocrinology. In: Biological Psychiatry, (H D’haenen, JA den Boer and P Willner, Eds), John Wiley & Sons, 97-110.
Gutman DA, Musselman DL and Nemeroff CB. 2002. Neuropeptide alterations in depression and anxiety disorders. In: Handbook of Depression and Anxiety: A Biological Approach, (JA denBoer, JM AdSitsen and S Kasper, eds), Marcel Dekker, Inc. (in press).
Hamid EH, Hyde TM, Egan MF, Wolf SS, Herman MM, Nemeroff CB and Kleinman JE. 2002. Neurotensin receptor binding abnormalities in the entorhinal cortex in schizophrenia and affective disorders. Biol Psychiat 51:795-800.
Heim C and Nemeroff CB. 2002. Neurobiology of early life stress: clinical studies. Seminars in Clin. Neuropsychiat 7:147-159.
Heim C, Newport DJ, Wagner D, Wilcox MS, Miller AH and Nemeroff CB. 2002. The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. Depression & Anxiety 15:117-125.
Golden RN, Nemeroff CB, McSorley P, Pitts CD and Dube EM. 2002. Efficacy and tolerability of controlled release and immediate release paroxetine in the treatment of depression. J Clin Psychiat 63:577-584.
Kinkead B and Nemeroff CB. 2002. Neurotensin: an endogenous antipsychotic? Current Opinion in Pharmacology 2:99-103.
Mathew SJ, Coplan JD, Smith ELP, Scharf BA, Owens MJ, Nemeroff CB, Mann JJ, Gorman JM and Rosenblum LA. 2002. Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent primates as a function of timing of adverse early rearing. Stress 5:185-193.
Musselman DL, Marzec U, Davidoff M, Manatunga AM, Gao F, Reemsnyder A, Duggirala S, Larsen H, Taylor RW, Hanson and Nemeroff CB. 2002. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. Depression and Anxiety 15:91-101.
Nemeroff CB and Owens MJ. 2002. Treatment of mood disorders. Nature Neuroscience 5(suppl):1068-1070.
Nemeroff CB. 2002. Recent advances in the neurobiology of depression. Psychopharmacol Bull 36:6-23.
Nemeroff CB. 2002. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Hum Psychopharmacol Clin Exp 17:S13-S16.
Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y and Tran PV. 2002. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132.
Nemeroff CB and Gutman DA. 2002. Neuroendocrinological research in psychiatry. In: Psychiatry as a Neuroscience, (JJ Lopez Ibor, W Gaebel , M Maj and N Sartorius, Eds) John Wiley & Sons 91-124.
Nemeroff CB, Kinkead B and Goldstein J. 2002. Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. J Clin Psychiat 63:5-11.
Nemeroff CB and Putnam JS. 2002. Anticholinergics and amantadine. In: Comprehensive Textbook of Psychiatry, VIII Edition (B Sadock and V Sadock , eds), Lipppincott, Williams & Wilkins (in press).
Newport DJ, Stowe ZN and Nemeroff CB. 2002. Parental depression: animal models of an adverse life event. Am J Psychiat 159:1265-1283.
Owens MJ and Rosenbaum JF. 2002. Escitalopram: a second generation SSRI. CNS Spectrums 7(4S1):34-39, 2002.
Rosenblum LA, Smith ELP, Altemus M, Scharf BA, Owens MJ, Nemeroff CB, Gorman JM and Coplan JD. 2002. Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. Psychoneuroendocrinology 27:651-660.
Schatzberg AF, Garlow SJ and Nemeroff CB. 2002. Molecular and cellular mechanisms in depression. In: Neuropsychopharmacology, The Fifth Generation of Progress (DS Charney, JT Coyle, KL Davis and CB Nemeroff, Eds), 1039-1050.
Stout SC, Owens MJ and Nemeroff CB. 2002. Regulation of CRF gene expression and peptide concentrations by stress and chronic antidepressant treatment. J. Pharmacology & Experimental Therapeutics 300:1085-1092.
Stout SC, Owens MJ and Nemeroff CB. 2002. Response to letter to the editor. Neuropsychopharmacology 26:413-414.
Vythilingam M, Heim C, Newport DJ, Miller AH, Anderson E, Vermetten E, Bronen R, Staib L, Charney DS, Nemeroff CB and Bremner JD. 2002. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiat 159:2072-2080.
2001
Berger J, Compton MT and Nemeroff CB. 2001. Treating the depressed suicidal patient. Directions in Psychiatry 21:33-43.
Binder E, Kinkead B, Owens MJ and Nemeroff CB. 2001. Neurotensin and dopamine interactions. Pharmacological Reviews 53:453-486.
Binder E, Kinkead B, Owens MJ, Kilts CD and Nemeroff CB. 2001. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neuroscience 21:601-608.
Binder EB, Kinkead B and Nemeroff CB. 2001. Neuropeptides. In: Current Issues in the Psychopharmacology of Schizophrenia, (A Brier, PV Tran, J Herrera, F Bymaster, G Tollefson, Eds), Lippincott Williams & Wilkins, Baltimore MD, 349-371.
Binder EB, Kinkead B, Owens MJ and Nemeroff CB. 2001. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biological Psychiatry 50:856-872.
Binder EB, Kinkead B, Owens MJ, Kilts CD and Nemeroff CB. 2001. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neurosci 21:601-608.
Coplan JD, Smith ELP, Altemus M, Scharf BA, Owens MJ, Nemeroff CB, Gorman JM and Rosenblum LA. 2001. Variable foraging demand rearing: sustained elevations in cisternal cerebrospinal fluid corticotropin-releasing factor concentrations in adult primates. Biological Psychiatry 50:200-204.
DeVane CL and Nemeroff CB. 2001. An evaluation of risperidone drug interactions. J Clin Psychopharmacol 21:408-416.
DeVane CL and Nemeroff CB. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinetics 40:509-522.
Ressler KJ and Nemeroff CB. 2001. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectrums 6:663-670
Stowe ZN, Cohen LS, Ritchie JC, Owens MJ and Nemeroff CB. 2001. Letters to the editor. American Journal of Psychiatry 158:144-145.
Stout SC, Owens MJ and Nemeroff CB. 2001. Neurokinin1 receptor antagonists as potential antidepressants. Annual Reviews in Pharmacology & Toxicology 41:877-906.
Owens MJ, Knight BS and Nemeroff CB. 2001. Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological Psychiatry 50:345-350.
Gutman DA, Owens MJ and Nemeroff CB. 2001. CRF receptor antagonists: a new approach to the treatment of depression. Pharmaceutical News 8:18-25.
Mandell AJ, Selz KA, Owens MJ, Shlesinger MF, Gutman DA and Arcuragi V. 2001. Hydrophobic mode-targeted, algorithmically designed peptide ligands as modulators of protein thermodynamic structure and function. In: Drug-Receptor Thermodynamics: Introduction and Applications (RB Raffa, ed.), John Wiley & Sons, New York, pp. 655-700.
Martarello L, Kilts CD, Ely T, Owens MJ, Nemeroff CB, Camp M and Goodman MM. 2001. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nuclear Medicine and Biology 28:187-195.
Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS and Nemeroff CB. 2001. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiat 158:1252-1257.
Musselman DL, Lawson DH, Gumnick JF, Manatunga A, Penna S, Goodkin R, Greiner K, Nemeroff CB and Miller AH. 2001. Paroxetine for the prevention of depression induced by high dose interferon-alpha. New Engl J Med 344:961-966.
Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R and Pitts CD. 2001. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiat 158:906-12.
O’Brien D, Skelton KH, Owens MJ and Nemeroff CB. 2001. Are CRF receptor antagonists potential antidepressants? Human Psychopharmacology 16:81-87.
Owens MJ and Nemeroff CB. 2001. An old transmitter in a new millennium. CNS Spectrums 6:655.
Owens MJ and Risch SC. 2001. Atypical antipsychotics. In: Essentials of Clinical Psychopharmacology (AF Schatzberg and CB Nemeroff, Eds.), American Psychiatric Association Press, Washington, DC, pp 125-154.
Radke JM, Owens MJ and Nemeroff CB. 2001. The effects of glutamate receptor agonists on neurotensin release using in vivo microdialysis. Eur J Pharmacol 411:129-134.
Ressler KJ and Nemeroff CB. 2001. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectrums 6:663-670.
.Stout SC, Owens MJ, Lindsey KP, Knight DL and Nemeroff CB. 2001. Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology 24:624-631.
2000
Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW and Owens MJ. 2000. Chronic administration of the selective CRF1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharmacology & Experimental Therapeutics 294:588-597.
Compton MT and Nemeroff CB. 2000. The treatment of Bipolar depression. J Clin Psychiat 61(9)57-67.
Coplan JD, Smith ELP, Trost RC, Scharf B, Altemus M, Bjornson L, Owens MJ, Gorman JM, Nemeroff CB and Rosenblum LA. 2000. Growth hormone response to clonidine in adversely reared young adult primates: relationship to serial cerebrospinal fluid corticotropin-releasing factor concentrations. Psychiatry Research 95:93-102.
Garlow SJ, Owens MJ, Kelsey J and Nemeroff CB. 2000. Nefazodone. In: Comprehensive Textbook of Psychiatry/VII (BJ Sadock and VA Sadock, Eds.), Lippincott Williams and Wilkins, Baltimore, pp. 2412-2418.
Gumnick J and Nemeroff CB. 2000. Problems with currently available antidepressants. J Clin Psychiat 61(10):5-15.
Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, Votaw J, Ely TD, Lambert P, Owens MJ, Camp VM, Malveaux E and Hoffman JM. 2000. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nuclear Medicine & Biology 27:1-12.
Gutman DA, Owens MJ and Nemeroff CB. 2000. Corticotropin-releasing factor antagonists as novel psychotherapeutics. Drugs of the Future 25:923-931.
Kinkead B, Binder EB and Nemeroff CB. 2000. Olanzapine and neurotensin. In: Olanzapine (Zyprexa) – A Novel Antipsychotic. (PV Tran, F Bymaster, N Tye , J Herrera, A Breier and G Tollefson, Eds), Lippincott Williams & Wilkins Healthcare, Philadelphia , 197-213
Kinkead B, Owens MJ and Nemeroff CB. 2000. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain. J. Pharmacology & Experimental Therapeutics 295:67-73.
Kinkead B, Lorch SM, Owens MJ and Nemeroff CB. 2000. Sex- and estrous cycle-related differences in the effects of acute antipsychotic drug administration on neurotensin-containing neurons in the rat brain. J. Pharmacology & Experimental Therapeutics 295:205-211.
Owens MJ, Knight DL and Nemeroff CB. 2000. Paroxetine binding to the rat norepinephrine transporter in vivo. Biological Psychiatry 47:842-845.
Owens MJ, Nemeroff CB and Knight DL. 2000. Correspondence: Paroxetine binding to the rat norepinephrine transporter in vivo. Biological Psychiatry 48:954-956.
Owens MJ, Nemeroff CB and Bissette G. 2000. Neuropeptides: biology and regulation. In: Comprehensive Textbook of Psychiatry/VII (BJ Sadock and VA Sadock, Eds.), Lippincott Williams and Wilkins, Baltimore, pp. 60-70.
Skelton KH, Nemeroff CB and Owens MJ. 2000. A comparison of plasma alprazolam concentrations following different routes of chronic administration in the Sprague-Dawley rat: implications for psychotropic drug research. Psychopharmacology 151:72-76.
Skelton KH, Owens MJ and Nemeroff CB. 2000. The neurobiology of urocortin. Regulatory Peptides 93:85-92.
Skelton KH, Nemeroff CB, Knight DL and Owens MJ. 2000. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20:1240-1248.
Stout SC, Mortas P, Owens MJ, Nemeroff CB and Moreau J-L. 2000. Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. European J. Pharmacology 401:39-46.
Stout SC, Owens MJ, Lindsey KP, Knight DL and Nemeroff CB. 2001. Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacol 24:624-631.
Stowe ZN, Cohen LS, Hostetter AM, Ritchie JC, Owens MJ and Nemeroff CB. 2000. Paroxetine in human breast milk and nursing infants. Am J Psychiat 157:185-189
Stowe ZN, Llewellyn A, Hostetter A and Nemeroff CB. 2000. The use of psychiatric medications during breastfeeding. In: Mood disorders in women (M steiner, K Yonkers E Eriksson, Eds) 329-351.
Thrivikraman KV, Nemeroff CB and Plotsky PM. 2000. Sensitivity to glucocorticoid-mediated fast-feedback regulation of the hypothalamic-pituitary-adrenal axis is dependent upon stressor specific neurocircuitry. Brain Res 870:87-101.
Vythilingam M, Anderson GM, Owens MJ, Halaszynski TM, Bremner JD, Carpenter LL, Heninger GR, Nemeroff CB and Charney DS. 2000. Cerebrospinal fluid corticotropin-releasing hormone (CRH) in healthy human: effects of yohimbine and naloxone. J. Clinical Endocrinology & Metabolism 85:4138-4145.
Xing D, Chen P, Keil R, Kilts CD, Shi B, Camp VM, Malveaux G, Ely T, Owens MJ, Votaw J, Davis M, Hoffman JM, BaKay RAE, Subramanian T, Watts RL and Goodman MM. 2000. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2b-carbo-1'-fluoro-2-propoxy-3b-(4-chlorophenyl)tropanes: ligands for the imaging of dopamine transporters by positron emission tomography. J. Medicinal Chemistry 43:639-648.
1999
Anand KJS, Coskun V, Thrivikraman KV, Nemeroff CB and Plotsky, PM. 1999. Long-term behavioral effects of repetitive pain in neonatal rat pups. Physiol Behav 66:627-637.
Arborelius L, Owens, MJ, Plotsky PM and Nemeroff CB. 1999. The role of corticotropin-releasing factor (CRF) in depression and anxiety disorders. J Endocrinol 160:1-12.
Berns GS and Nemeroff CB. 1999. The neurobiology of bipolar disorder. Odyssey 5:36-41.
DeVane CL and Nemeroff CB. 1999. Psychotropic drug interactions. In: Psychiatric Treatment of the Medically Ill, RG Robinson and WR Yates, Eds, Marcel Dekker, Inc., New York , 523-543.
Ehlers CL, Somes C, Li T-K, Lumeng L, Kinkead B, Owens MJ and Nemeroff CB. 1999. Neurotensin studies in alcohol naive, preferring and non-preferring rats. Neurosci 93:227-236.
Garlow SJ, Musselman DL and Nemeroff CB. 1999. Neurochemistry of mood disorders: clinical studies. In: The Neurobiology of Mental Illness, (DS Charney, EJ Nestler and BS Bunney, Eds), Oxford University Press, 348-364
Garlow SJ and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: trazodone. In: Comprehensive Textbook of Psychiatry Seventh edition (V Sadock and B Sadock, Eds) Williams and Wilkins, Baltimore, 2482-2490.
Garlow SJ, Owens MJ and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: nefazodone. In: Comprehensive Textbook of Psychiatry Seventh edition (V Sadock and B Sadock, Eds) Williams and Wilkins, Baltimore, 2412-2418.
Graham Y, Heim C, Goodman SH, Miller AH and Nemeroff CB. 1999. The effects of neonatal stress on brain development: implications for psychopathology. Development and Psychopathology 11:545-565.
Heim C and Nemeroff CB. 1999. The impact of early adverse experiences on brain systems involved in anxiety and affective disorders. Biol Psychiat 46:1509-1522.
Heit S, Graham Y and Nemeroff CB. 1999. Neurobiological effects of early trauma. The Harvard Mental Health Letter 16:4-6.
Kelsey JE and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: an overview. In: Comprehensive Textbook of Psychiatry, VII edition (V Sadock and B Sadock, Eds), Williams & Wilkins, Baltimore, 2432-2435.
Kelsey JE and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: citalopram. In: Comprehensive Textbook of Psychiatry, VII edition (V Sadock and B Sadock, Eds),Williams & Wilkins, Baltimore , 2435-2438.
Kelsey JE and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: fluoxetine. In: Comprehensive Textbook of Psychiatry, VII edition (V Sadock and B Sadock, Eds), Williams & Wilkins, Baltimore, 2438-2444
Kelsey JE and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: fluvoxamine. In: Comprehensive Textbook of Psychiatry, VII edition (V Sadock and B Sadock, Eds), Williams & Wilkins, Baltimore, 2444-2446
Kelsey JE and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: paroxetine. In: Comprehensive Textbook of Psychiatry, VII edition (V Sadock and B Sadock, Eds), Williams & Wilkins, Baltimore, 2447-2451
Kelsey JE and Nemeroff CB. 1999. Selective serotonin reuptake inhibitors: sertraline. In: Comprehensive Textbook of Psychiatry, VII edition (V Sadock and B Sadock, Eds), Williams & Wilkins, Baltimore, 2451-2455
Kinkead B, Binder E and Nemeroff CB. 1999. Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiat 46:340-351.
Lee DO, Abramowitz AJ and Nemeroff CB. 1999. Attention deficit hyperactivity disorder. In: Treatment Algorithms in Psychopharmacology (K Jobson, D Stein and J Fawcett, Eds), John Wiley & Sons, Ltd., 165-179.
McDonald WM, Tupler LA, Marsteller FA, Figiel GS, DiSouza , Nemeroff CB and Krishnan KRR. 1999. Hyperintense lesions on magnetic resonance images in bipolar disorder. Biol Psychiat 45:965-971.
Musselman DL, McDaniel JS, Porter MR and Nemeroff CB. 1999. Screening for depression in the medical setting. Journal of the Medical Association of Georgia. 2:47-53.
Nemeroff CB. 1999. The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer’s disease: up with CRF, down with acetylcholine. Arch Gen Psychiat 56:991-992.
Nemeroff CB. 1999. The preeminent role of early untoward experience on vulnerability to major psychiatric disorders: the nature-nurture controversy revisited and soon to be resolved. News and Views, Molecular Psychiatry 4:106-108.
Nemeroff CB, Kilts CD and Berns GS. 1999. Functional brain imaging: 21 st century phrenology or psychobiological advance for the millennium. Editorial, Am J Psychiat 156:671-673.
Newport DJ and Nemeroff CB. 1999. Treatment of depression in the cancer patient. Clinical Geriatrics 7:40-55
Owens MJ and Nemeroff CB. 1999. Corticotropin releasing factor antagonists in affective disorders. Expert Opinions on Investigational Drugs 8:1849-1858.
Owens MJ and Nemeroff CB. 1999. Corticotropin-releasing factor antagonists: therapeutic potential in the treatment of affective disorders. CNS Drugs 12:85-92.
Owens MJ, Nemeroff CB and Bissette G. 1999. Neuropeptides: biology, regulation, and role in neuropsychiatric disorders. In: Comprehensive textbook of Psychiatry, Seventh Edition (V Sadock and B sadock, Eds) williams and Wilkins, Baltimore, 60-70 .
Ressler KJ and Nemeroff CB. 1999. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiat 46:1219-1233.
VanSant SP, Risby ED and Nemeroff CB. 1999. Stress, hormones and aging. In: Endocrinology of Aging, JE Morley, Ed., 63-71. \